Oragenics, Inc. OGEN
0.49
(0.01)
(2.00%)
as of 25 Sep
- Market cap
- $2.3M
- P/E
- 0.4×
Follow OGEN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
3.97 | 4.73 | 4.67 | 2.12 | |
Current Ratio |
4.42 | 5.64 | 5.73 | 3.01 | |
Net Debt/EBITDA |
3.65 | 3.36 | 2.71 | 1.49 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.97 | 1.24 | 1.00 | 0.86 | |
Capex/Depreciation |
0.00 | 0.00 | — | — | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.91) | (1.31) | (0.51) | (0.49) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.91) | (1.31) | (0.51) | (0.49) | |
Cash per Share |
7.31 | 3.89 | 1.42 | 0.87 | |
Shareholders Equity per Share |
6.30 | 3.84 | 1.44 | 0.83 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.30 | 3.84 | 1.44 | 0.83 | |
Free Cash Flow |
(2.98) | (2.84) | (2.20) | (2.19) | |
Working Capital |
9.83 | 8.28 | 6.18 | 3.67 | |
Net Current Asset Value |
9.83 | 8.28 | 6.18 | 3.67 | |
EV/EBIT |
— | — | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
| Other line items | |||||
Average Receivables |
— | 0.04 | — | — | |
Average Payables |
2.04 | 1.46 | 1.21 | 1.54 | |
Average Assets |
8.95 | 5.77 | 5.68 | 3.82 | |
Average Common Equity |
5.66 | 4.03 | 3.16 | 0.77 |
Columns are period end dates